Key Drivers
- Gross Margin
- Cash Burn
- Balance Sheet
AIAI Summary
PHAT has shifted from a speculative pipeline story to a commercial execution test: rapid VOQUEZNA-driven revenue growth and the pHalcon-EoE-201 catalyst could support a move toward Q3 2026 profitability, but heavy debt, negative equity, and ongoing cash burn mean the stock only works if growth accelerates fast enough to self-fund the next phase.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Cash Burn
- •Balance Sheet
PHAT shows strong gross margins and rising revenue, but persistent net losses, negative cash flow, and a strained balance sheet mean the business is still not converting growth into sustainable profitability. క
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Key support
- •Breakout needed
PHAT is showing constructive but fragile upside momentum, with a last-month high, higher lows, and support at $10.50-$10.60, but it still needs a clean break above $11.20 to confirm a durable breakout.
Sharp pullbacks within a quick rebound to a last-month high suggest short-term volatility risk
Sentiment & News
Key News Insights:
- •Ahead-of-schedule enrollment
- •EoE trial milestone
- •Q4 data watch
Phathom Pharmaceuticals finished enrollment ahead of schedule in its Phase 2 pHalcon-EoE-201 VOQUEZNA trial for eosinophilic esophagitis, with topline results expected in Q4 2026.
This is a modestly positive update for Phathom, reflecting strong trial execution and keeping a key clinical catalyst on track
Similar Companies in Healthcare
Other companies in the same sector with AI ratings